The median recurrence-free and overall survival years of APOA1 rs670 A/A carrying breast cancer patients were both longer than the standard chemotherapy duration (~1 year) and the advised 5-year limit for continuous TAM usage. This evidence concerns the gene APOA1 and breast carcinoma.